Trans-arterial radioembolization with yttrium-90 microspheres (TARE with Y90) is a treatment for patients with liver cancers, but requires the evaluation of lung shunting fraction (LSF). Currently, LSF is estimated using a separate invasive “dry-run” with a transient radioactive Technetium-99m macroaggregated albumin (Tc-99m-MAA) that doubles the cost and risk of TARE. This study proposes to predict LSF from dynamic contrast enhanced MRI (DCE MRI) and perfusion quantification. Our preliminary data demonstrated that it is feasible to estimate LSF as measured by Tc-99m-MAA from noninvasive DCE MRI using quantitative transport mapping (QTM) velocity.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords